Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

157
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
157
Cancer Survival Analysis01:21

Cancer Survival Analysis

418
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
418
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

226
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
226
Clinical Trials01:16

Clinical Trials

6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

174
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
174

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

[Application of Bayesian statistics in AIDS epidemic estimation].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2020
Same author

[Comparison of heart failure and COVID-19 in chest CT features and clinical characteristics].

Zhonghua xin xue guan bing za zhi·2020
Same author

[Exploration of potential beneficial people of neoadjuvant chemotherapy based on clinical staging in gastric cancer: a single center retrospective study].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2020
Same author

Drug Efficacy of Ivermectin Against Primary Nematodes Parasitizing Captive Przewalski's Horse (<i>Equus Ferus Przewalskii</i>) after Ten Years of Annually Treatment.

Helminthologia·2020
Same author

Isolation and characterization of Streptococcus suis strains from swine in Jiangsu province, China.

Journal of applied microbiology·2020

Related Experiment Video

Updated: Aug 21, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.8K

[Evaluation considerations for using surrogate endpoints in anticancer clinical trials].

Y Y Song1, L Tang1, L Xia1

  • 1Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|November 16, 2022
PubMed
Summary

Accelerated drug approval uses surrogate endpoints to speed up cancer drug development. This strategy addresses limitations of overall survival, improving clinical trial efficiency and patient access to novel therapies.

Keywords:
Anti-cancer drugsClinical trialDrug evaluationSurrogate endpoints

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.5K

Related Experiment Videos

Last Updated: Aug 21, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.5K

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Biostatistics

Context:

  • Overall survival (OS) is the gold standard for anti-cancer drug efficacy but leads to prolonged clinical trials.
  • Cancer types with good prognoses require lengthy follow-up for OS, delaying new drug development.
  • OS can be confounded by subsequent treatments, complicating efficacy assessment.

Purpose:

  • To discuss the challenges and strategies for utilizing surrogate endpoints in oncology clinical trials.
  • To provide insights into confirming and rationally applying surrogate endpoints for anti-cancer drug approval.
  • To enhance the efficiency and accelerate the development of novel anti-tumor therapeutics.

Summary:

  • This review examines the use of surrogate endpoints as an alternative to overall survival in cancer clinical trials.
  • It addresses the limitations of OS, including extended trial durations and confounding factors.
  • The authors focus on the critical aspects of validating and implementing surrogate endpoints within the drug review process.

Impact:

  • Optimizing surrogate endpoint utilization can expedite the regulatory approval of new anti-cancer drugs.
  • Improved clinical trial design using surrogate endpoints will accelerate the delivery of innovative cancer treatments to patients.
  • This approach aims to enhance the overall quality and speed of anti-tumor drug development and market entry.